Kratom Research Institute

Policy · 2026-02-10

UConn Pharmacologist Leads Fight to Separate Synthetic 7-OH From Natural Leaf Kratom in Law

Source: UConn Magazine

Why it matters

A leading pharmacologist is building a regulatory framework to distinguish natural kratom leaf from synthetic 7-OH products — an effort that could shape legislation in multiple states and spare millions of leaf users from blanket bans.

The big picture

The rise of 7-hydroxymitragynine (7-OH) products in 2023 created a regulatory crisis: products labeled as kratom began causing opioid-level addictions and deaths, prompting state bans that made no distinction between the natural leaf and synthetic derivatives. Dr. C. Michael White at UConn has studied kratom since 2017 and now chairs the Kratom Consumer Advisory Council (KCAC), an independent body working to establish safety standards and guide evidence-based regulation.

Key findings

What they say

"While not risk-free, natural leaf kratom offers an accessible option, and many users report that it helps them regain control of their lives. We need a balanced, thoughtful regulatory environment to support people with opioid use disorder and chronic pain." — Dr. C. Michael White, UConn Professor of Pharmacy and KCAC Chair

Bottom line

A UConn pharmacologist is spearheading a regulatory push to schedule synthetic 7-OH as a Schedule I drug while preserving legal access to natural kratom leaf — and his advocacy is already shaping state laws.